Fibrinolysis for patients with intermediate-risk pulmonary embolism. - Université de Bretagne Occidentale Access content directly
Journal Articles New England Journal of Medicine Year : 2014

Fibrinolysis for patients with intermediate-risk pulmonary embolism.

Eric Vicaut
Erich Bluhmki
  • Function : Author
Benjamin Brenner
  • Function : Author
Claudia Dellas
  • Function : Author
Klaus Empen
  • Function : Author
Ana Franca
  • Function : Author
Nazzareno Galiè
  • Function : Author
David Jimenez
Matija Kozak
  • Function : Author
Christian Kupatt
  • Function : Author
Nils Kucher
  • Function : Author
Irene M Lang
  • Function : Author
Mareike Lankeit
  • Function : Author
Massimiliano Palazzini
  • Function : Author
Antoniu Petris
  • Function : Author
Piotr Pruszczyk
  • Function : Author
Matteo Rugolotto
  • Function : Author
Aldo Salvi
  • Function : Author
Bozena Sobkowicz
  • Function : Author
Branislav S Stefanovic
  • Function : Author
Holger Thiele
Adam Torbicki
  • Function : Author
Franck Verschuren
Stavros V Konstantinides
  • Function : Author
  • PersonId : 958824

Abstract

BACKGROUND: The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. METHODS: In a randomized, double-blind trial, we compared tenecteplase plus heparin with placebo plus heparin in normotensive patients with intermediate-risk pulmonary embolism. Eligible patients had right ventricular dysfunction on echocardiography or computed tomography, as well as myocardial injury as indicated by a positive test for cardiac troponin I or troponin T. The primary outcome was death or hemodynamic decompensation (or collapse) within 7 days after randomization. The main safety outcomes were major extracranial bleeding and ischemic or hemorrhagic stroke within 7 days after randomization. RESULTS: Of 1006 patients who underwent randomization, 1005 were included in the intention-to-treat analysis. Death or hemodynamic decompensation occurred in 13 of 506 patients (2.6%) in the tenecteplase group as compared with 28 of 499 (5.6%) in the placebo group (odds ratio, 0.44; 95% confidence interval, 0.23 to 0.87; P=0.02). Between randomization and day 7, a total of 6 patients (1.2%) in the tenecteplase group and 9 (1.8%) in the placebo group died (P=0.42). Extracranial bleeding occurred in 32 patients (6.3%) in the tenecteplase group and 6 patients (1.2%) in the placebo group (P<0.001). Stroke occurred in 12 patients (2.4%) in the tenecteplase group and was hemorrhagic in 10 patients; 1 patient (0.2%) in the placebo group had a stroke, which was hemorrhagic (P=0.003). By day 30, a total of 12 patients (2.4%) in the tenecteplase group and 16 patients (3.2%) in the placebo group had died (P=0.42). CONCLUSIONS: In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke. (Funded by the Programme Hospitalier de Recherche Clinique in France and others; PEITHO EudraCT number, 2006-005328-18; ClinicalTrials.gov number, NCT00639743.).

Dates and versions

hal-01045144 , version 1 (24-07-2014)

Identifiers

Cite

Guy Meyer, Eric Vicaut, Thierry Danays, Giancarlo Agnelli, Cecilia Becattini, et al.. Fibrinolysis for patients with intermediate-risk pulmonary embolism.. New England Journal of Medicine, 2014, 370 (15), pp.1402-11. ⟨10.1056/NEJMoa1302097⟩. ⟨hal-01045144⟩
366 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More